The role of DNA repair capacity in susceptibility to lung cancer: A review

Cancer and Metastasis Reviews

Volumn 16, Issue 3-4, 1997, Pages 295-307

  Wei, Qingyi ^a,b   Spitz, Margaret R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; DNA repair capacity; Lung cancer; Molecular epidemiology; Risk assessment; Susceptibility

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CARCINOGEN; CYTOCHROME P450; DIHYDROXYBENZO[A]PYRENE OXIDE; DNA; GLUTATHIONE TRANSFERASE; MUTAGENIC AGENT; PHOSPHORUS 32;

CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME ABERRATION; CIGARETTE SMOKING; DNA ADDUCT; DNA REPAIR; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOBACCO;

EID: 0030668586     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1005852211430     Document Type: Review

References (110)

1. Ames BN, Durston W, Yamasaki E, Lee F: Carcinogens are mutagens: A simple test system combining liver homogenates for activation and bacteria for detection. Proc Natl Acad Sci USA 70: 2281-2285, 1973
2. Schmid W: The micronucleus test for cytogenetic analysis. In: Hollaender A (ed) Chemical Mutagens, Vol. 4. Plenum Press, New York, 1976, pp. 31-53
3. Abe S, Sasaki M: Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells exposed to various chemicals. J Natl Cancer Inst 58: 1635-1641, 1977
4. McCann J, Choi E, Yamasaki E, Ames BN: Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals. Proc Natl Acad Sci USA 72: 5135-5139, 1975
5. Henderson BE, Ross RK, Pike MC: Toward the primary prevention of cancer. Science 254: 1131-1138, 1991
6. Bishop JM: Molecular themes in oncogenesis. Cell 64: 235-248, 1991
7. Levine AJ: The tumor suppressor genes. Ann Rev Biochem 62: 623-651, 1993
8. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996
9. Hartwell LH, Weinert TA: Checkpoints: Controls that assure the order of cell cycle events. Science 246: 629-633, 1989
10. Farber E: The multistep nature of cancer. Cancer Res 44: 4217-4223, 1984
11. Fearon ER, Vogelstein BA: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990
12. Correa P: Human gastric carcinogenesis: A multistep and multifactorial process. First American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 52: 6735-6740, 1992
13. Sancer A: DNA repair in humans. Ann Rev Genetics 29: 69-105, 1995
14. Hoeijmakers JHJ: Human nucleotide excision repair syndromes: Molecular clues to unexpected intricacies. Eur J Cancer 30: 1912-1921, 1994
15. Modrich P: Mismatch repair, genetic stability, and cancer. Science 266: 1959-1960, 1994
16. Alcalay J, Freedman SE, Goldberg LH, Wolf JE: Excision repair of pyrimidine dimers induced by simulated solar radiation in the skin of patients with basal cell carcinoma. J Invest Dermatol 95: 506-509, 1990
17. Wei Q, Matanoski GM, Farmer ER, Hedayati M, Grossman L: DNA repair and aging in basal cell carcinoma: A molecular epidemiologic study. Proc Natl Acad Sci USA 90: 1614-1618, 1993
18. Hall J, English DR, Artuso M, Armstrong BK, Winter M: DNA Repair capacity as a risk factor for non-melanocytic skin cancer - a molecular epidemiological study. Int J Cancer 58: 179-184, 1994
19. Shopland DR, Eyre HJ, Pechacek TF: Smoking-attributable cancer mortality in 1991: Is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 83: 1142-1148, 1991
20. Tokuhata GK, Lilienfeld AM: Familial aggregation of lung cancer in humans. J Natl Cancer Inst 30: 289-312, 1963
21. Ooi WL, Elston RC, Chen VW, Bailey-Wilson JE, Rothschild H: Increased familial risk for lung cancer. J Natl Cancer Inst 76: 217-222, 1986
22. Sellers TA, Elston RC, Rothschild H: Familial risk of cancer among randomly selected cancer probands. Genet Epidemiol 5: 381-392, 1988
23. Sellers TA, Bailey-Wilson JE, Elston RC, Wilson AF, Elston GZ, Ooi WL, Rothschild H: Evidence for Mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst 82: 1272-1279, 1990
24. Carmelli D, Swan GE, Robinerre D, Fabsitz R: Genetic influence on smoking - a study of male twins. N Engl J Med 327: 829-833, 1992
25. Sellers TA, Potter JD, Bailey-Wilson JE, Rich SS, Rothschild H, Elsta RC: Lung cancer detection and prevention: Evidence for an interaction between smoking and genetic predisposition. Cancer Res 52: 2696-2697, 1992
26. Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW: Human CYP1A1 gene: Cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 48: 720-725, 1991
27. Jaiswal AK, Gonzalez FJ, Nebert DW: Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo(a)pyrene metabolism. Nucleic Acids Res 13: 4503-4520, 1985
28. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Walanabe J: Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 263: 131-133, 1990
29. Hayashi S, Watanabe J, Nakachi K, Kawajiri K: Genetic linkage of lung cancer-associated Msp1 polymorphisms with amino acid replacement in the heme binding region of the human eytochrome P450IA1 gene. J Biochem 110: 407-411, 1991
30. Cosma G, Crofts F, Taioli E, Toniolo P, Garte S: Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 40: 309-316, 1993
31. Crofts F, Cosma GN, Currie D, Taiolo E, Toniolo P, Garte SJ: A novel CYP11 gene polymorphism in African-Americans. Carcinogenesis 14: 1729-1731, 1993
32. Paigen B, Ward E, Steenland K, Houten L, Gurtoo HL, Minowafa J: Arylhydrocarbon hydroxylase in cultured lymphocytes of twins. Am J Hum Genet 30: 561-571, 1978
33. Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus AM, Castegnaro M, Alexandrov K, Rojas M, Saracci R, Giuntini C: Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: Results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 98: 119-124, 1992
34. Bartsch H, Hietanen E, Petruzzelli S, Giuntini C, Saracci R, Mussi A, Angeletti CA: Possible prognostic value of pulmonary AH-locus-linked enzymes in patients with tobacco-related lung cancer. Int J Cancer 46: 185-188, 1990
35. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ: A tobacco smoke-derived nitrosamine, 4-(methylnitrosa-mine)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 12: 1197-1201, 1991
36. Kellerman G, Luyten-Kellerman M, Shaw CR: Genetic variation of arylhydrocarbon hydroxylase in human lymphocytes. Am J Hum Genet 25: 327-331, 1973
37. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL: Positive correlation between high aryl hydrocarbon hydroxylase activity in primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 42: 5030-5037, 1982
38. Kelsey K, Wiencke JK, Spitz MR: A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans. Carcinogenesis 15: 1121-1124, 1994
39. London SJ, Daly AK, Fairbrother KS, Holmes C, Carpenter CL, Navidi WC, Idle JR: Lung cancer risk in African Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Res 55: 6035-6037, 1995
40. Shields PG, Caporaso NE, Falk RT, Sugimura U, Trivers GE, Trump BF, Hoover RN, Weston A, Harris CC: Lung cancer, race, and CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 2: 481-485, 1993
41. Hirvonen A, Husgafvel Pursiainen K, Anttila S, Karjalainen A, Sorsa M, Vainio H: Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 2: 259-263, 1992
42. Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC: Cytochrome P4501A1 Msp1 polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5: 687-692, 1996
43. Nakachi K, Imai K, Hayashi S, Kawajiri K: Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53: 2994-2999, 1993
44. Amos CI, Caporaso NE, Weston A: Host factors in lung cancer risk: A review of interdisciplinary studies. Cancer Epidemiol Biomarkers Prev 1: 505-513, 1992
45. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H: PCR-Based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 3: 19-27, 1993
46. Caporaso NE, Shields PG, Landi MT, Shaw GL, Tucker MA, Hoover R, Sugimura H, Weston A, Harris CC: The debrisoquine metabolic phenotype and DNA-based assays: Implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect 98: 101-105, 1992
47. Law MR, Hetzel MR, Idle JR: Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 59: 686-687, 1989
48. Tiano HF, Wang RL, Hosokawa M, Crespi C, Tindall KR, Langenbach R: Human CYP2A6 activation of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK): Mutational specificity in the gpt gene of AS52 cells. Carcinogenesis 15: 2859-2866, 1994
49. Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, Bell DA: Ethnic variation in the CYP2E1 gene: Polymorphism analysis of 695 African-Americans. European-Americans and Taiwanese. Pharmacogenetics 4: 185-195, 1994
50. Uematsu F, Ikawa S, Kikuchi H, Sagami I, Kanamaru R, Abe T, Satoh K, Motomiya M, Watanabe M: Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: Possible relevance to low smoking exposure. Pharmacogenetics 4: 58-63, 1994
51. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vainio H: The human CYP2E1 gene and lung cancer: Dral and Rsal restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 14: 85-88, 1993
52. Watanabe J, Yang JP, Eguchi H, Hayashi S, Imai K, Nakachi K, Kawajiri K: An Rsa I polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population. Jpn J Cancer Res 86: 245-248, 1995
53. Sugimura H, Hamada GS, Suzuki I, Iwase T, Kiyokawa E, Kino I, Tsugane S: CYP1A1 And CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil. Pharmacogenetics 5: S145-148, 1995
54. Persson I, Johansson I, Bergling H, Dahl ML, Seidegard J, Rylander R, Rannug A, Hogberg J, Sundberg MI: Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 319: 207-211, 1993
55. Brockmoller J, Gross D, Kerb R, Drakoulis N, Roots I: Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reaction. Biochem Pharmacol 43: 647-650, 1992
56. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP, Kadlubar FF: The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 98: 87-94, 1992
57. Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ: Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis 11: 33-36, 1990
58. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett GJ, Wathen CG, Wolf CR, Spurr NK: Glutathione S-transferase mu locus: Use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 12: 1533-1537, 1991
59. Kihara M, Noda K, Okamoto N: Increased risk of lung cancer in Japanese smokers with class mu glutathione S-transferase gene deficiency. Cancer Lett 71: 151-155, 1993
60. Nazar-Stewart V, Motulsky AG, Eaton DL, White E, Hornung SK, Leng ZT, Stapleton P, Weiss NS: The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 53: 2313-2318, 1993
61. Heckbert SR, Weiss NS, Hornung SK, Eaton DL, Motulsky AG: Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst 84: 414-422, 1992
62. Brockmoller J, Kerb R, Drakoulis N, Nitz M, Roots I: Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res 53: 1004-1011, 1993
63. Meyer DJ, Coles B, Pemble SE, Gilmore KS, Fraser GM, Ketterer B: Theta, a new class of glutathione transferases purified from rat and man. Biochem J 274: 409-414, 1991
64. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB: Human glutathione S-transferase theta (GSTT1): cDNA Cloning and the characterization of a genetic polymorphism. Biochem J 300:271-276, 1994
65. Trizna Z, Clayman GL, Spitz MR, Briggs KL, Goepfert H: Glutathione S-transferase genotypes as risk factors for head and neck cancer. Am J Surg 170: 499-501, 1995
66. Blum M, Demierre A, Grant DM, Heim M, Meyer UA: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 88: 5237-5241, 1991
67. Martinez C, Agundez JA, Olivera M, Martin R, Ladero JM, Benitez J: Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 5: 207-214, 1995
68. Vineis P, Landi MT, Caporaso N: Metabolic polymorphisms and the cancer risk: The evaluation of epidemiological studies. Med Lav 83: 557-575, 1992
69. Petruzzelli S, Franchi M, Gronchi L, Janni A, Oesch F, Pacifici GM, Giuntini C: Cigarette smoke inhibits cytosolic but not microsomal epoxide hydrolase of human lung. Hum Exp Toxicol 11: 99-103, 1992
70. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ: The human microsomal epoxide hydrolase gene (EPHX1): Complete nucleotide sequence and structural characterization. Hum Mol Genet 3: 421-428, 1994
71. Hagmar L, Brogger A, Hansteen IL, Heim S, Hogstedt B, Knudsen L, Lambert B, Linnainmaa K, Mitelman F, Nordenson I, Reuterwall C, Salomaa S, Skerfving S, Sorsa M: Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 54: 2919-2922, 1994
72. Hsu TC, Johnston DA, Cherry LM, Ramkissoon D, Schantz SP, Jessup JM, Winn RJ, Shirley L, Furlong C: Sensitivity to genotoxic events of bleomycin in humans: Possible relationship to environmental carcinogens. Int J Cancer 43: 403-409, 1989
73. Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA: Mutagen sensitivity as a biologic marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 4: 99-103, 1995
74. Wei Q, Gu J, Cheng L, Bondy ML, Spitz MR, Hsu TC: Benzo[a]pyrene diol epoxide induced chromosomal aberrations in normal human lymphocytes. Cancer Res 56: 3975-3979, 1996
75. Wei Q, Spitz MR, Gu J, Cheng L, Xu X, Strom SS, Kripke ML, Hsu TC: DNA repair capacity correlates with mutagen sensitivity in lymphoblastoid cell lines. Cancer Epidemiol Biomarkers Prev 5: 199-204, 1996
76. Protic-Sabljic M, Kraemer KH: One pyrimidine dimer inactivates expression of a transfected gene in xeroderma pigmentosum cells. Proc Natl Acad Sci USA 82: 6622-6626, 1985
77. Cleaver JE, Kraemer K: Xeroderma pigmentosum. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic Basis of Inherited Diseases II. McGraw-Hill Inc., New York, 1989, pp. 2949-2971
78. Friedberg EC: DNA Repair. WH Freeman and Company, New York, 1985
79. Phillips DH: Fifty years of B[a]P. Nature 333: 468-472, 1983
80. Gelboin HV: Benzo[a]pyrene metabolism, activation, and carcinogenesis: Role and regulation of mixed function oxidases and related enzymes. Physiol Rev 60: 1107-1166, 1980
81. MacLeod MC, Tang MS: Interaction of benzo[a]pyrene-diol-epoxides with linear and supercoiled DNA. Cancer Res 45: 51-56, 1985
82. Jernstrom B, Graslund A: Covalent binding of benzo[a]-pyrene-7,8-dihydrodiol-9,10-epoxide to DNA: Molecular structure, induced mutations and biological consequences. Biophys Chem 49: 185-199, 1994
83. Cosman M, de los Santos C, Fiala R, Hingerty BE, Sigh SB, Ibanez V, Margulis LA, Live D, Geacintov NE, Broyde S, Petel DJ: Solution conformation of the major adducts between the carcinogen (+)-anti-benzo[a]pyrene diol epoxide and DNA. Proc Natl Acad Sci USA 89: 1914-1918, 1992
84. Tang MS, Pierce JR, Doisy RP, Nazimiec ME, MacLeod MC: Differences and similarities in the repair of two benzo-[a]pyrene diol epoxide isomers induced DNA adducts by uvrA, uvrB, and uvrC gene products. Biochemistry 31: 8429-8436, 1992
85. Sancer A: Mechanisms of DNA excision repair. Science 266: 1954-1956, 1994
86. Athas WF, Hedayati M, Matanoski GM, Farmer ER, Grossman L: Development and field-test validation of an assay for DNA repair in circulating human lymphocytes. Cancer Res 51: 5786-5793, 1991
87. Wei O, Malanoski GM, Farmer ER, Hedayali MA, Grossman L: DNA Repair and susceptibility to skin cancer. Am J Epidemiol 140: 589-607, 1994
88. Wei O, Matanoski GM, Farmer ER, Hedayati MA, Grossman L: DNA Repair related to multiple skin cancers and drug use. Cancer Res 54: 437-440, 1994
89. Wei Q, Cheng L, Hong WK, Spitz MR: Reduced DNA repair capacity in lung cancer patients. Cancer Res 56: 4103-4107, 1996
90. Li D, Wang M, Cheng L, Spitz MR, Hittelman WN, Wei O: In vitro induction of benzo[a]pyrene diol epoxide-induced DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. Cancer Res 56: 3638-3641, 1996
91. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 7: 1543-1551, 1986
92. Watson WP: Postradiolabeling for detection of DNA damage. Mutagenesis 2: 319-331, 1987
93. Phillips DH, Hewer A, Grover PL: Aromatic DNA adducts in human bone marrow and peripheral blood leukocytes. Carcinogencsis 7: 2071-2075, 1986
94. Phillips DH, Hewer A, Martin CN, Garner RC, King MM: Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 336: 790-792, 1988
95. 32P-Postlabeling test for covalent DNA binding of chemicals in vivo. Application to a variety of aromatic carcinogenes and methylating agents. Carcinogenesis 5: 231-243, 1984
96. van Schooten FJ, Hillebrand MJ, van Leeuwen FE, van Zandwijk N, Jansen HM, den Engelse L, Kriek E: Polycyclic aromatic hydrocarbon-DNA adducts in white blood cells from lung cancer patients: No correlation with adduct levels in the lung. Carcinogenesis 13: 987-993, 1992
97. 32P-postlabeling assay. Carcinogenesis 12: 503-508, 1991
98. Gupta RC, Earley K, Sharma S: Use of human peripheral blood lymphocytes to measure DNA binding capacity of chemical carcinogens. Proc Natl Acad Sci USA 85: 3513-3517. 1988
99. Everson RB, Randerath E, Santella RM, Cefalo RC, Avitts TA, Randerath K: Detection of smoking-related covalent DNA adducts in human placenta. Science 231: 54-59, 1986
100. 32P-postlabeling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and ex-smokers. Carcinogenesis 12: 1301-1305, 1991
101. Barret JM, Calsou P, Salles B: Deficient nucleotideexcision repair activity in protein extracts from normal human lymphocytes. Carcinogenesis 7: 1611-1616, 1995
102. Krolewski B, Little JB, Reynolds RJ: Effect of duration of exposure to benzo[a]pyrene diol-epoxide on neoplastic transformation, mutagenesis, cytotoxicity and total covalent binding to DNA of rodent cells. Teratog Carcinog Mutagen 8: 127-136, 1988
103. Vineis P, Caporaso N: Tobacco and cancer epidemiology and the laboratory. Environ Health Perspect 103: 156-160, 1995
104. Denissenko MF, Pao A, Tang M, Pfeifer GP: Preferential formation of benzo[a]pyrene adducts at lung mutational hotspots in p53. Science 274: 430-432, 1996
105. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 Mutations in human cancer. Science 53: 49-53, 1991
106. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994
107. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, Hittleman W, Hong WK: Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 2: 682-685, 1996
108. Mao L, Lee JS, Kurie JM, Khuri FR, Fan YH, Lippman SM, Lee JJ, Ro JY, Hittelman WN, Hong WK: Frequent genetic alterations in bronchial epithelium of smokers. Proceedings of the American Association Cancer Research (in press)
109. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM: The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85: 17-26, 1996
110. Wiencke JK, Kelsey KT, Varkonyi A, Semey K, Wain JC, Mark E, Christiani DC: Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. Cancer Res 55: 4910-4914, 1995